Effects of the Src kinase inhibitor saracatinib (azd0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 463-471

  Hannon, Rosemary A ^a   Clack, Glen ^b   Rimmer, Martin ^b   Swaisland, Alan ^b   Andrew Lockton, J ^b   Finkelman, Richard D ^b   Eastell, Richard ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bone turnover markers; Clinical trial; Men; Pharmacokinetics; Src kinase inhibitor

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CREATININE; MARKER; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE; 1,3 BENZODIOXOLE DERIVATIVE; BIOLOGICAL MARKER; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE; SARACATINIB;

ANOREXIA; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE TURNOVER; CHEST TIGHTNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS LINKING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; HEART PALPITATION; HUMAN; LIVER FUNCTION TEST; LOOSE FECES; MALE; METASTASIS; MYALGIA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; URINE LEVEL; ADULT; BLOOD; BONE REMODELING; DRUG ADMINISTRATION; DRUG EFFECTS; MEN'S HEALTH;

ADULT; BENZODIOXOLES; BIOLOGICAL MARKERS; BONE REMODELING; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; MALE; MEN'S HEALTH; QUINAZOLINES;

EID: 77953433829     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090830     Document Type: Article

References (24)

1. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358. (Pubitemid 36791891)
2. Horne WC, Sanjay A, Bruzzaniti A, et al. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev. 2005;208:106-125. (Pubitemid 41746388)
3. Sanjay A, Houghton A, Neff L, et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, α(v)β(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol. 2001;152:181-195.
4. Xing L, Venegas AM, Chen A, et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001;15:241-253. (Pubitemid 32107668)
5. Soriano P, Montgomery C, Geske R, et al. Targeted disruption of the csrc proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693-702. (Pubitemid 121001157)
6. Boyce BF, Yoneda T, Lowe C, et al. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992;90:1622-1627.
7. Marzia M, Sims NA, Voit S, et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol. 2000;151:311-320.
8. Green TP, Fennell M, Whittaker R, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol. 2009;3:248-261.
9. Li B, Boast S, de los Santos K, et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet. 2000;24:304-308.
10. de Vries TJ, Mullender MG, van Duin MA, et al. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res. 2009;7:476-488.
11. Eastell R, Hannon RA, Gallagher N, et al. The effect of AZD0530, a highly selective, orally available Src/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males [Abstract 3041]. J Clin Oncol. 2005;23.
12. Lockton JA, Smethurst D, Macpherson M, et al. Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor [Abstract 3125]. Proc Am Soc Clin Oncol. 2005;24.
13. Missbach M, Jeschke M, Feyen J, et al. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999;24:437-449. (Pubitemid 29234132)
14. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006;318:161-172. (Pubitemid 43920753)
15. Destaing O, Sanjay A, Itzstein C, et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol Biol Cell. 2008;19:394-404. (Pubitemid 351186162)
16. Alatalo SL, Ivaska KK, Waguespack SG, et al. Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem. 2004;50:883-890.
17. Recchia I, Rucci N, Funari A, et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-D]-pyrimidines induces osteoclast apoptosis in vivo and in vitro: involvement of ERK1/2 pathway. Bone. 2004;34:65-79.
18. Braga de Castro Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res. 1999;14:602-608.
19. Schaller S, Henriksen K, Sveigaard C, et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res. 2004;19:1144-1153. (Pubitemid 41110567)
20. Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, et al. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun. 2008;366:483-488.
21. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537-3540.
22. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056. (Pubitemid 37294942)
23. Boyce BF, Xing L, Shakespeare W, et al. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int. 2003;85:S2-S5. (Pubitemid 36605852)
24. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19:5636-5642.